Clinical Trials Browser

OTHER × Interventional × Doxorubicin × Clear all

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Phase 2 Recruiting

Sarcoma, Ewing, Osteosarcoma

NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2 Active not recruiting

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Phase 2 Completed

30 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00734877 2026-05-22

TT4B

Phase 3 Active not recruiting

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Phase 2 Active not recruiting

Multiple Myeloma

NCT01476410 2026-05-22

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Phase 2 Completed

49 enrolled 25 charts

Hodgkin Disease

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT02710734 2026-05-22

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Completed

Urothelial Carcinoma of the Bladder

NCT07049848 2026-05-22

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

Phase 2 Recruiting

Sarcoma

NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Phase 2 Not yet recruiting

Hodgkin Disease

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT07194044 2026-05-15

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing

NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03017326 2026-05-13

PHITT

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Phase 2 Active not recruiting

Neoplasms, Plasma Cell

NCT05453500 2026-05-11

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

Burkitt Lymphoma

NCT03150693 2026-05-08

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Recruiting

Burkitt Lymphoma

NCT05498896 2026-05-08

BARBICAN

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01840592 2026-05-06

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT01920932 2026-05-06

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT02488967 2026-05-06

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04043494 2026-05-06

LBL 2018

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04803201 2026-05-06

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT06023862 2026-05-06

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT01670500 2026-05-05

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

Phase 2 Completed

118 enrolled 23 charts

Breast Neoplasms

NCT04978584 2026-05-05

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05848765 2026-05-05

REFRACT

Phase 2 Recruiting

Lymphoma, Lymphoma, Follicular

NCT04478292 2026-05-04

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

Phase 3 Recruiting

Gastrointestinal

Hepatoblastoma

NCT06594939 2026-05-01

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04546620 2026-04-30

REMoDL-A

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06765317 2026-04-30

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT00558519 2026-04-29

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2 Completed

318 enrolled 9 charts

Other hematologic neoplasm

Leukemia

NCT05645380 2026-04-28

NeoTRACT

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

Rhabdomyosarcoma

NCT06249191 2026-04-24

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06434064 2026-04-24

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07243626 2026-04-24

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

Phase 2 Recruiting

Sarcoma

NCT03755804 2026-04-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT07097363 2026-04-23

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04968106 2026-04-21

TORNADO

Phase 2 Active not recruiting

Sarcoma

NCT04028063 2026-04-20

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Phase 2 Active not recruiting

Sarcoma

NCT01746238 2026-04-17

Bevacizumab/Doxorubicin/Radiation for Sarcoma

Phase 1 Active not recruiting

Sarcoma